GlobeNewsWire
16 Jul 2026, 07:36 UTC · 1h ago
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
16 Jul 2026, 07:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Angelini Pharma has completed the acquisition of Catalyst Pharmaceuticals (CPRX). — The completion of the merger eliminates the uncertainty of the deal closing and integrates Catalyst's portfolio into Angelini.
+0.60Blackstone is investing 1 billion euros in preferred equity to support the transaction. — Significant backing from a major global private equity firm validates the strategic value of the acquisition.
+0.40CDP Equity is investing approximately 1 billion euros to acquire a 23.5% stake in Angelini Pharma's common equity. — Strong institutional support from a state-backed entity provides financial stability and strategic alignment for the company's expansion.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The acquisition establishes Angelini Pharma's presence in the U.S. market and expands its brain health and rare disease platform. — Entering the U.S. market is a material growth driver that increases the company's total addressable market and revenue potential.
Which stocks this story touches
The company was acquired by Angelini Pharma, expanding its reach and integrating into a larger global platform.
Blackstone is investing 1 billion euros in preferred equity as part of a strategic acquisition.
Morgan Stanley served as the sole financial advisor for the transaction.
The bank acted as the sole global coordinator and underwriter for the financing package.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
